BRPI0410963B8 - anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo - Google Patents

anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo

Info

Publication number
BRPI0410963B8
BRPI0410963B8 BRPI0410963A BRPI0410963A BRPI0410963B8 BR PI0410963 B8 BRPI0410963 B8 BR PI0410963B8 BR PI0410963 A BRPI0410963 A BR PI0410963A BR PI0410963 A BRPI0410963 A BR PI0410963A BR PI0410963 B8 BRPI0410963 B8 BR PI0410963B8
Authority
BR
Brazil
Prior art keywords
antibody
ctgf
polynucleotide
pharmaceutical composition
microorganism
Prior art date
Application number
BRPI0410963A
Other languages
English (en)
Inventor
Y Lin Ai
A Yeowell David
A Oliver Noelynn
Wang Qingjian
B Neff Thomas
R Usinger William
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of BRPI0410963A publication Critical patent/BRPI0410963A/pt
Publication of BRPI0410963B1 publication Critical patent/BRPI0410963B1/pt
Publication of BRPI0410963B8 publication Critical patent/BRPI0410963B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

anticorpo isolado ou porção biologicamente ativa deste, linhagem celular, composição farmacêutica, métodos de neutralizar uma atividade biológica de ctgf e de tratar ou prevenir um distúrbio associado com ctgf, anticorpo quimérico, medicamento, sequência de polinucleotídeo, polinucleotídeo recombinante, e, célula hospedeira. a presente invenção diz respeito aos anticorpos que se ligam ao ctgf. os anticorpos são particularmente direcionados às regiões do ctgf envolvidas em atividades biológicas associadas com fibrose. a invenção também diz respeito aos métodos de usar os anticorpos para tratar os distúrbios associados com o ctgf incluindo os distúrbios fibróticos localizados e sistêmicos incluindo aqueles do pulmão, fígado, coração, pele, e rim.
BRPI0410963A 2003-06-04 2004-06-02 anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo BRPI0410963B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47559803P 2003-06-04 2003-06-04
US10/858,186 US7405274B2 (en) 2003-06-04 2004-06-01 Connective tissue growth factor antibodies
PCT/US2004/017080 WO2004108764A2 (en) 2003-06-04 2004-06-02 Connective tissue growth factor antibodies

Publications (3)

Publication Number Publication Date
BRPI0410963A BRPI0410963A (pt) 2006-07-04
BRPI0410963B1 BRPI0410963B1 (pt) 2019-10-08
BRPI0410963B8 true BRPI0410963B8 (pt) 2021-05-25

Family

ID=33493433

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410963A BRPI0410963B8 (pt) 2003-06-04 2004-06-02 anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo

Country Status (17)

Country Link
US (9) US7405274B2 (pt)
EP (3) EP1631591B1 (pt)
JP (2) JP5624707B2 (pt)
KR (1) KR101244113B1 (pt)
CN (2) CN1829740B (pt)
AT (1) ATE538136T1 (pt)
AU (1) AU2004245514B2 (pt)
BR (1) BRPI0410963B8 (pt)
CA (1) CA2526509C (pt)
DK (1) DK1631591T3 (pt)
ES (1) ES2379662T3 (pt)
HK (1) HK1094336A1 (pt)
IL (1) IL172328A (pt)
NO (1) NO336451B1 (pt)
NZ (1) NZ543522A (pt)
RU (1) RU2330861C2 (pt)
WO (1) WO2004108764A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
CA2555789A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
US20050271670A1 (en) * 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
CA2606778A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Vascular disease therapies
CN101316626A (zh) * 2005-09-29 2008-12-03 菲布罗根公司 用于降低血压的方法
JP2008295328A (ja) * 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010042202A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
WO2010042201A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of focal segmental glomerulosclerosis
EP2221387A1 (en) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
US8771692B2 (en) * 2009-07-02 2014-07-08 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) * 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US20140065162A1 (en) * 2011-11-08 2014-03-06 Fibrogen, Inc. Compositions and Methods for Treating Brain Tumors
JP6040943B2 (ja) * 2011-12-22 2016-12-07 アステラス製薬株式会社 新規抗ヒトｃｔｇｆ抗体
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
EP2844291B1 (en) * 2012-05-03 2019-02-13 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
KR102221499B1 (ko) * 2013-09-26 2021-03-02 갈데르마 소시에떼아노님 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
WO2016037071A2 (en) 2014-09-05 2016-03-10 Rxi Pharmaceuticals Corporation Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
CN104740628B (zh) * 2015-02-12 2017-09-26 西安交通大学医学院第一附属医院 用于治疗肝纤维化的结缔组织生长因子嵌合疫苗及其应用
EP3307775A4 (en) 2015-06-15 2018-12-05 The Board of Trustees of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
EP3386544B1 (en) 2015-12-10 2020-11-25 Fibrogen, Inc. Methods for treatment of motor neuron diseases
AU2017284198B2 (en) * 2016-06-13 2023-09-28 The University Of North Carolina At Chapel Hill Optimized CLN1 genes and expression cassettes and their use
WO2019221576A1 (ko) * 2018-05-17 2019-11-21 광주과학기술원 Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물
JPWO2020009248A1 (ja) * 2018-07-04 2021-08-12 京都府公立大学法人 眼組織の線維化抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
EP3981787A4 (en) 2019-06-04 2022-09-14 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODIES AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS USE
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
CN115286713A (zh) * 2020-10-27 2022-11-04 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
TW202227485A (zh) * 2020-12-03 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 一種含抗結締組織生長因子抗體的醫藥組成物
CN115645525B (zh) * 2022-12-14 2023-04-14 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587670A (en) 1897-08-03 Combined high-pressure throttle and reducing valve
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0783243B1 (en) 1994-09-15 2001-02-21 Fred Nordberg Electric fence device
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
KR20010085767A (ko) 1998-09-08 2001-09-07 추후 보정 결합 조직 성장 인자를 조정, 조절 및 억제함에 의하여신장 장애를 검출, 예방 및 치료하는 방법
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU773278B2 (en) 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CN1589403B (zh) * 2001-09-18 2011-06-01 法布罗根股份有限公司 测定结缔组织生长因子的方法
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法

Also Published As

Publication number Publication date
US20160257740A1 (en) 2016-09-08
AU2004245514A1 (en) 2004-12-16
DK1631591T3 (da) 2012-04-10
ES2379662T3 (es) 2012-04-30
US20090017043A1 (en) 2009-01-15
JP5753506B2 (ja) 2015-07-22
US20040248206A1 (en) 2004-12-09
CN1829740B (zh) 2013-05-29
CA2526509A1 (en) 2004-12-16
NZ543522A (en) 2008-06-30
NO20060027L (no) 2006-01-03
CA2526509C (en) 2013-08-06
EP1631591B1 (en) 2011-12-21
RU2330861C2 (ru) 2008-08-10
US20160024198A1 (en) 2016-01-28
JP2012143239A (ja) 2012-08-02
BRPI0410963B1 (pt) 2019-10-08
US7405274B2 (en) 2008-07-29
BRPI0410963A (pt) 2006-07-04
US20110091468A1 (en) 2011-04-21
AU2004245514B2 (en) 2009-10-01
EP1631591A2 (en) 2006-03-08
US20240076364A1 (en) 2024-03-07
WO2004108764A3 (en) 2005-03-03
US7871617B2 (en) 2011-01-18
IL172328A (en) 2012-01-31
EP2322549A1 (en) 2011-05-18
RU2005141492A (ru) 2007-07-20
HK1094336A1 (en) 2007-05-04
US9034643B2 (en) 2015-05-19
NO336451B1 (no) 2015-08-24
WO2004108764A2 (en) 2004-12-16
KR101244113B1 (ko) 2013-03-18
US20190023778A1 (en) 2019-01-24
CN1829740A (zh) 2006-09-06
JP5624707B2 (ja) 2014-11-12
US20210230259A1 (en) 2021-07-29
ATE538136T1 (de) 2012-01-15
EP2338914A1 (en) 2011-06-29
CN103539858A (zh) 2014-01-29
US20140073047A1 (en) 2014-03-13
KR20060030032A (ko) 2006-04-07
JP2007525194A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
BRPI0410963B8 (pt) anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo
CN109803977B (zh) 核酸产品及其施用方法
BR112019012040A2 (pt) anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73.
BRPI0412637A (pt) anticorpos, método de seleção de um anticorpo de hvegf, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, método de uso do anticorpo e método de tratamento de um mamìfero
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2022167816A3 (en) Antibodies
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
WO2005113005A3 (en) Transcutaneous and/or transdermal transport of materials
MXPA05006034A (es) Proteina de duplicacion.
BRPI0410875A (pt) método de inibição do crescimento de tumor com anticorpos de fator antitecido
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
BR112022020942A2 (pt) Métodos de tratamento de infecções virais usando arginase
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067221, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI